U.S. To Support Non-Clinical Studies, Clinical Trial Of Janssen’s Investigational COVID-19 Vaccine

HHS: HHS Accelerates Clinical Trials, Prepares for Manufacturing of COVID-19 Vaccines
“The U.S. Department of Health and Human Services took steps [Monday] to speed the development and manufacturing of vaccines to prevent COVID-19, working with New Jersey-based Janssen Research & Development, part of Johnson & Johnson, and Moderna of Cambridge, Massachusetts. The Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR), will support non-clinical studies and a Phase 1 clinical trial of Janssen’s COVID-19 investigational vaccine, Ad26 SARS-CoV-2. This clinical trial will examine the vaccine’s safety in healthy adult volunteers and its ability to induce an immune response in the recipients…” (3/30).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.